CI

At a glance

ClinicalIndex Comparison Record
Phase 2Unknown· 120 target
Drug / intervention
MSCsbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02083731
NCT02083731Phase 2Unknown
CompareCT.gov

Mesenchymal Stem Cells for Treatment of CMV Infection After Hematopoietic Stem Cell Transplant

Nanfang Hospital, Southern Medical University·interventional·Posted Mar 11, 2014·Updated Jan 7, 2015

In Brief

A Phase 2 clinical trial evaluating MSCs for Stem Cell Transplantation, Hematopoietic and 2 related conditions. Targeting 120 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the efficacy of mesenchymal stem cells (MSC) in the treatment of refractory cytomegalovirus (CMV) infection after allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStem Cell Transplantation, Hematopoietic, CMV Infection, Hematological Diseases
CountriesChina
CollaboratorsAcademy Military Medical Science, China, Peking University People's Hospital, Sun Yat-sen University, Guangdong Provincial People's Hospital, Guangzhou General Hospital of Guangzhou Military Command, Third Affiliated Hospital, Sun Yat-Sen University, Shanghai Zhongshan Hospital

Timeline

Phase 2UnknownOverdue
2014201520162017201820192020202120222023202420252026
First PostedMar 11, 2014
Enrollment StartJan 1, 2014
Primary CompletionJan 1, 2016
Study CompletionJan 1, 2017
TodayJul 1, 2026
Enrollment to primary: 2 yearsPosted 12.3 years ago

Interventions

MSCsbiological